Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease

被引:8
作者
Gritsch, Herbert [1 ]
Schrenk, Gerald [1 ]
Weinhappl, Nina [1 ]
Mellgard, Bjorn [2 ]
Ewenstein, Bruce [2 ]
Turecek, Peter L. [3 ,4 ]
机构
[1] Baxalta Innovat GmbH, Pharmaceut Sci, Vienna, Austria
[2] Takeda Dev Ctr Amer Inc, Rare Genet & Hematol, Res & Dev, Cambridge, MA USA
[3] Univ Vienna, Dept Pharmaceut Sci, Div Pharmacol, Vienna, Austria
[4] Baxalta Innovat GmbH, Plasma Derived Therapies Res & Dev, Vienna, Austria
来源
JOURNAL OF BLOOD MEDICINE | 2022年 / 13卷
关键词
agar; electrophoresis; factor VIII; plasma; von Willebrand diseases; von Willebrand factor; VONWILLEBRAND-FACTOR; BINDING; MANAGEMENT; DIAGNOSIS; SAFETY;
D O I
10.2147/JBM.S377126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recombinant von Willebrand factor (rVWF, vonicog alfa) is a purified VWF concentrate produced from Chinese hamster ovary cells. rVWF is not exposed to the VWF-cleaving protease ADAMTS13 and so is not subject to proteolytic degradation of large (L) and ultra-large (UL) VWF multimers by that enzyme.Purpose: To compare the structure and function of rVWF with the human plasma-derived VWF [pdVWF] concentrates Haemate P (R)/ Humate-P (R), Voncento (R), Wilate (R)/Eqwilate (R), and Wilfactin (R)/Willfact (R); to investigate the relationship between VWF multimeric pattern and VWF:ristocetin cofactor (VWF:RCo) activity through population pharmacokinetic (PK) modeling in patients with severe von Willebrand disease (VWD) treated with rVWF.Methods: Analyses included VWF:RCo activity, VWF:collagen-binding activity, VWF:platelet glycoprotein Ib receptor binding, factor VIII (FVIII) binding capacity, and VWF-mediated platelet adhesion under flow conditions. VWF multimeric structure was determined by agarose gel electrophoresis. Population PK models describing the activity-time profile of small, medium, and L/UL multimers following intravenous administration of rVWF in patients with severe VWD were developed.Results: Findings demonstrate that rVWF contains a non-degraded VWF multimer pattern including the UL multimers not present in pdVWF concentrates. rVWF displayed higher specific platelet-binding activity, and faster mediation of platelet adhesion to collagen under shear stress versus pdVWF concentrates. rVWF also demonstrated higher FVIII binding capacity than Haemate P (R), Voncento (R) and Wilate (R). Modeling provided evidence that VWF:RCo activity in patients with severe VWD treated with rVWF is associated with L/UL VWF multimers in the circulation.Conclusions: Findings suggest that the L and UL multimers preserved in rVWF contribute to high biological activity and might be important for providing hemostatic efficacy.
引用
收藏
页码:649 / 662
页数:14
相关论文
共 43 条
[11]  
European Medicines Agency, 2007, GUID REP RES POP PHA
[12]  
Federici AB, 2008, HAEMOPHILIA, V14, P5, DOI 10.1111/j.1365-2516.2007.01610.x
[13]   BINDING OF VONWILLEBRAND-FACTOR TO GLYCOPROTEIN-IB AND IIB/IIIA COMPLEX - AFFINITY IS RELATED TO MULTIMERIC SIZE [J].
FEDERICI, AB ;
BADER, R ;
PAGANI, S ;
COLIBRETTI, ML ;
DEMARCO, L ;
MANNUCCI, PM .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (01) :93-99
[14]   Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII [J].
Fischer, BE ;
Kramer, G ;
Mitterer, A ;
Grillberger, L ;
Reiter, M ;
Mundt, W ;
Dorner, F ;
Eibl, J .
THROMBOSIS RESEARCH, 1996, 84 (01) :55-66
[15]   Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease [J].
Franchini, Massimo ;
Mannucci, Pier Mannuccio .
EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (09) :825-830
[16]   TRIPLET STRUCTURE OF VON-WILLEBRAND-FACTOR REFLECTS PROTEOLYTIC DEGRADATION OF HIGH-MOLECULAR-WEIGHT MULTIMERS [J].
FURLAN, M ;
ROBLES, R ;
AFFOLTER, D ;
MEYER, D ;
BAILLOD, P ;
LAMMLE, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) :7503-7507
[17]   von Willebrand factor: molecular size and functional activity [J].
Furlan, M .
ANNALS OF HEMATOLOGY, 1996, 72 (06) :341-348
[18]   Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease [J].
Gill, Joan C. ;
Castaman, Giancarlo ;
Windyga, Jerzy ;
Kouides, Peter ;
Ragni, Margaret ;
Leebeek, Frank W. G. ;
Obermann-Slupetzky, Ortrun ;
Chapman, Miranda ;
Fritsch, Sandor ;
Pavlova, Borislava G. ;
Presch, Isabella ;
Ewenstein, Bruce .
BLOOD, 2015, 126 (17) :2038-2046
[19]   The genetic basis of von Willebrand disease [J].
Goodeve, Anne C. .
BLOOD REVIEWS, 2010, 24 (03) :123-134
[20]  
GRALNICK HR, 1981, BLOOD, V58, P387